Department of Thoracic Surgery, Kanagawa Cancer Center, Yokohama, Japan.
Department of Pathology, Kanagawa Cancer Center, Yokohama, Japan.
Thorac Cancer. 2021 Jan;12(2):194-200. doi: 10.1111/1759-7714.13743. Epub 2020 Nov 13.
The Oncomine Dx Target Test (ODxTT) is a next-generation sequencing-based companion diagnostic test which has been recently developed; however, its analysis success rate could be improved, especially for small samples. The aim of this study was to identify the pathological factors associated with biopsy specimens that affect the analysis success rate of ODxTT.
We retrospectively investigated 119 cases subjected to ODxTT at Kanagawa Cancer Center. Data pertaining to the results of BRAF V600E mutation analysis in ODxTT and pathological factors based on microscope slides were collected. Pathological factors including tissue surface area, tumor cell count, and tumor content rate were assessed. We constructed receiver operating characteristic curves and determined the optimal cutoff values of each pathological factor. Multivariate logistic analysis was used to identify significant factors.
A total of 98 of 119 samples were successfully analyzed (75.6%). The tissue surface area and tumor cell count were significantly higher in the group associated with analysis success (P < 0.001 and P = 0.011, respectively), and their optimal cutoff values were 1.04 mm and 375 cells, respectively. A tissue surface area > 1.04 mm and tumor cell count >375 cells had a positive effect on the analysis success rate of ODxTT (odds ratio [OR] 0.10; 95% confidence interval [CI]: 0.03-0.35; P < 0.001 and OR 0.25; 95% CI: 0.07-0.90; P = 0.033, respectively).
Selecting samples with a tissue surface area > 1.04 mm and a tumor cell count >375 cells might improve the analysis success rate of ODxTT.
Significant findings of the study: We found that a tissue surface area > 1.04 mm and tumor cell count >375 cells had a positive effect on the analysis success rate of ODxTT in the analysis of biopsy tissue samples.
It is sometimes necessary to assess genetic alterations with a small biopsy sample in daily practice. The criteria mentioned above will help to determine which tests should be performed, ODxTT or multiple single-gene testing.
OncomineDxTargetTest(ODxTT)是一种最近开发的基于下一代测序的伴随诊断测试;然而,其分析成功率可以提高,尤其是对于小样本。本研究的目的是确定影响 ODxTT 分析成功率的与活检标本相关的病理因素。
我们回顾性调查了在神奈川癌症中心进行 ODxTT 的 119 例病例。收集了 ODxTT 中 BRAFV600E 突变分析结果以及基于显微镜载玻片的病理因素数据。评估了组织表面积、肿瘤细胞计数和肿瘤含量率等病理因素。我们构建了受试者工作特征曲线,并确定了每个病理因素的最佳截断值。采用多变量逻辑分析确定显著因素。
在 119 例样本中,共有 98 例(75.6%)成功分析。与分析成功相关的组中,组织表面积和肿瘤细胞计数显著更高(P<0.001 和 P=0.011),其最佳截断值分别为 1.04mm 和 375 个细胞。组织表面积>1.04mm 和肿瘤细胞计数>375 个细胞对 ODxTT 分析成功率有积极影响(比值比[OR]0.10;95%置信区间[CI]:0.03-0.35;P<0.001 和 OR0.25;95%CI:0.07-0.90;P=0.033)。
选择组织表面积>1.04mm 和肿瘤细胞计数>375 个细胞的样本可能会提高 ODxTT 的分析成功率。
研究的重要发现:我们发现,在分析活检组织样本时,组织表面积>1.04mm 和肿瘤细胞计数>375 个细胞对 ODxTT 的分析成功率有积极影响。
在日常实践中,有时需要用小的活检样本评估基因改变。上述标准将有助于确定应进行哪些测试,是 ODxTT 还是多个单基因测试。